Comparative Pharmacology
Head-to-head clinical analysis: OXYCET versus VICOPROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXYCET versus VICOPROFEN.
OXYCET vs VICOPROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, though it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Acetaminophen is believed to produce analgesia through central action, possibly mediated through inhibition of cyclooxygenase (COX) and activation of descending serotonergic pathways, though the exact mechanism is not fully understood.
Hydrocodone is a mu-opioid receptor agonist that activates G-protein coupled opioid receptors, leading to analgesia; ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis.
1 tablet (325 mg acetaminophen and 5 mg oxycodone) orally every 4 to 6 hours as needed for pain; maximum 12 tablets per day.
1 tablet (hydrocodone 5 mg / ibuprofen 200 mg) orally every 4 to 6 hours as needed for pain; maximum 5 tablets per day.
None Documented
None Documented
The terminal elimination half-life of oxycodone is approximately 3.5-4 hours for immediate-release formulations. For controlled-release formulations, the half-life is similar due to absorption-limited elimination, but the duration of action is extended due to the formulation. In elderly patients or those with hepatic impairment, half-life may be increased up to 2-fold.
Hydrocodone: 3.8-4.5 hours (immediate-release); clinical context: analgesic duration correlates with half-life, but may be prolonged in renal/hepatic impairment. Ibuprofen: 2-4 hours (immediate-release); clinical context: anti-inflammatory effect may outlast plasma half-life due to tissue distribution.
Oxycodone is primarily metabolized in the liver via CYP3A4 to noroxycodone and via CYP2D6 to oxymorphone. Renal excretion accounts for approximately 87% of the administered dose, with 8.1% as unchanged oxycodone, 22.8% as noroxycodone, 9.1% as noroxymorphone, 3.2% as oxymorphone, and others. Fecal excretion is about 10%.
Hydrocodone: primarily renal (26% as unchanged drug and metabolites, including norhydrocodone, hydromorphone, and conjugates); less than 5% fecal. Ibuprofen: renal (50-60% as unchanged drug and metabolites, mainly conjugated with glucuronic acid; <10% unchanged); biliary/fecal (minor).
Category C
Category C
Opioid Analgesic Combination
Opioid Analgesic Combination